# Rafał Dziadziuszko

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/rafa-dziadziuszko/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,905 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 61 |
| i10-index | 189 |
| Last Known Institution | University of Gdańsk |
| OpenAlex ID | https://openalex.org/A5054931755 |
| ORCID iD | https://orcid.org/0000-0001-8080-9843 |
| Works | 603 |

## Researcher papers

- [Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-versus-crizotinib-in-untreated-i-alk-i-positive-non-small-cell-lung/)
- [Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study](https://scholariq.org/papers/updated-overall-survival-and-final-progression-free-survival-data-for-patients/)
- [Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/rociletinib-in-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer](https://scholariq.org/papers/liquid-biopsy-for-advanced-nsclc-a-consensus-statement-from-the-international/)
- [Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-ros1-fusion-positive-non-small-cell-lung-cancer-integrated/)
- [Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer](https://scholariq.org/papers/tarlatamab-for-patients-with-previously-treated-small-cell-lung-cancer/)
- [Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-in-resected-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study](https://scholariq.org/papers/alectinib-versus-chemotherapy-in-crizotinib-pretreated-anaplastic-lymphoma/)
- [Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus](https://scholariq.org/papers/managing-cancer-patients-during-the-covid-19-pandemic-an-esmo-multidisciplinary/)
- [Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/repotrectinib-in-i-ros1-i-fusion-positive-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [University of Gdańsk](https://scholariq.org/institutions/university-of-gdansk/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.